What pricing strategy allowed Alexion's Soliris, a treatment for rare blood disorders, to become one of the world's most expensive drugs at over $500,000 per patient annually?

In the pharmaceutical industry, pricing strategies can significantly impact both patient access and company profitability. 'Orphan drugs' represent a fascinating case study in medical product pricing. These medications treat rare diseases affecting small patient populations, yet they often command premium prices. Test your knowledge about this specialized pricing strategy that has transformed the economics of rare disease treatment.

This is a live public trivia poll on AIPolls.Net. Vote and see real-time results.

Value-based pricing justified by life-saving efficacy and the extreme rarity of target conditions
Loss-leader pricing to gain market share before introducing more profitable follow-up medications
Bundle pricing combining multiple rare disease treatments into a single payment package
Subscription-based pricing where hospitals pay a fixed annual fee for unlimited patient access